Posted on 26/02/2010 in Animal Health Supplier News Dechra has published its financial report for the six-month period ending on December 31st 2009, during which the firm saw improvements in its business performance.
The animal health company's revenue for the period was 184.8 million pounds, a 6.7 per cent increase on the 173.2 million takings in the corresponding period of 2008.
Improving performance in its European veterinary pharmaceutical sales was partly credited for this growth, with the firm highlighting the strong performance of brands such as Felimazole and Vetivex.
Non-executive chairman Michael Redmond and chief executive Ian Page said that volume growth for the period was encouraging despite the weak economy.
They added: "With the ongoing introduction of new products, our increasing penetration of international markets and a robust product development pipeline, we remain optimistic for the group's future prospects."
Last month, Zeneus Pharma and EUSA Pharma founder Bryan Morton joined Dechra as a non-executive chairman.Other news stories from 26/02/2010
Read more in the Zenopa News Archive
How this news is generated
|
